TheraRadar
← Back
Data updated: Jun 28, 2026

BAUSCH

Specialty
DermatologyImmunologyOphthalmology Execution: Good

BAUSCH is a specialty pharmaceutical company focused on Dermatology, Immunology, Ophthalmology. Key products include LUZU.

1946
Since
84
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
41 Small Molecules

BAUSCH at a Glance

  • Fast trial execution (16 months median completion)

BAUSCH's Key Drugs

BAUSCH's core commercial portfolio centers on LUZU, DUOBRII, ARAZLO, spanning Dermatology and Immunology — its most strategically important drugs approved in the last 15 years.

LUZU
Infectious Disease

Tinea Pedis

Approved 2013
DUOBRII
Immunology

Plaque Psoriasis

RARα Approved 2019
ARAZLO
Dermatology

Acne Vulgaris

RARα Approved 2019
JUBLIA
Infectious Disease

Onychomycosis

Approved 2014
BRYHALI
Immunology

Plaque Psoriasis

Approved 2018

BAUSCH's Recent FDA Approvals

New NDA/BLA approvals for BAUSCH over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

BAUSCH's Therapeutic Areas

BAUSCH's approved drugs and pipeline span 5 therapeutic areas, led by Dermatology and Immunology, across 0 biologic and 41 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Dermatology 30%
11 drugs Phase 3: 11 Phase 2: 6 Phase 1: 10
Immunology 28%
5 drugs Phase 3: 17 Phase 2: 9 Phase 1: 9
Ophthalmology 18%
0 drugs Phase 3: 14 Phase 2: 7 Phase 1: 12
Cardiovascular 13%
6 drugs Phase 3: 4 Phase 2: 1 Phase 1: 3
Gastroenterology 11%
2 drugs Phase 3: 7 Phase 2: 2 Phase 1: 6

BAUSCH's Top Competitors

BAUSCH's closest competitors by therapeutic-area and drug-target overlap include Novartis, BAUSCH AND LOMB INC, and MALLINCKRODT. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

Novartis big-pharma
Cardiovascular, Ophthalmology, Immunology
BAUSCH AND LOMB INC other
Ophthalmology, Cardiovascular, Dermatology, Immunology
MALLINCKRODT specialty
Immunology, Gastroenterology, Cardiovascular, Dermatology
Bayer big-pharma
Cardiovascular, Ophthalmology, Dermatology
B BRAUN specialty
Ophthalmology, Dermatology, Cardiovascular

BAUSCH Pipeline Snapshot

BAUSCH has 118 active clinical programs from ClinicalTrials.gov — 53 Phase 3, 25 Phase 2 and 40 Phase 1.

53
Phase 3
25
Phase 2
40
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • LUZU leads revenue
  • • 5 key drugs tracked
View revenue breakdown →

Trial Catalysts

  • • Dermatology pipeline focus
  • • Phase 3 readout tracking
View full pipeline →

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis
View patent timeline →

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison
Compare with competitor →

Execution Intelligence

  • • Phase 3: 38/51 completed
  • • Speed: 16 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges